What is Assertio Holdings, Inc. (ASRT)?

Assertio Holdings, Inc. (ASRT) is a stock in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry. View full analysis on Stocks360.

What is the current price of ASRT?

The current price of ASRT is $23.50. Prices are updated in real time on Stocks360.

What is ASRT's price-to-earnings (PE) ratio?

ASRT's trailing twelve-month PE ratio is -4.24, based on current price and earnings per share data available on Stocks360.

What is ASRT's market capitalization?

ASRT's market capitalization is $151,861,230.00, placing it in the small-cap tier.

Assertio Holdings, Inc. (ASRT)

Stock analysis · NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

$23.50

Market Cap

$151.86M

PE (TTM)

-4.24

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.53

Day Range

$23.48 – $23.50

52-wk Range

$8.61 – $23.50

Avg Volume

N/A

Volume

270.19K

Assertio Holdings, Inc. (ASRT) is a publicly traded company in the Healthcare sector. Latest price: $23.50. Market cap $151.86M. Trailing PE -4.24. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 6 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-29 · $1.16 2026-06-29 · $23.50 (+1929.36%)

Earnings

Most Recent

May 8, 2026

EPS $-2.93 vs est. $-1.91

Missed by $1.02

Proprietary Signals

Signal snapshot temporarily unavailable.

About Assertio Holdings, Inc.

Assertio Holdings, Inc. is a specialized pharmaceutical company focused on developing and commercializing therapeutic solutions across key medical domains, including neurology, hospital care, and pain and inflammation management. Among its portfolio, Assertio offers INDOCIN, available as both an oral solution and a suppository. This medication addresses conditions such as moderate to severe rheumatoid arthritis (including acute flare-ups), ankylosing spondylitis, osteoarthritis, acute painful shoulder, and gouty arthritis. The company's offerings also encompass CAMBIA, an NSAID specifically formulated to alleviate symptoms associated with migraine headaches, including nausea, light sensitivity (photophobia), and sound sensitivity (phonophobia). Zipsor, another NSAID, is indicated for managing mild to moderate acute pain. For more significant short-term pain relief, SPRIX, also an NSAID, provides analgesia comparable to opioid-level treatments for moderate to moderately severe pain. Rounding out its product line is Otrexup, a prescription methotrexate delivered via a convenient single-dose auto-injector. This therapy targets severe, active rheumatoid arthritis in adults and active…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-4.24×
P/S (TTM)	1.49×
P/B	2.00×
PEG	0.11×
P/FCF (TTM)	-21.45×
EV / EBITDA	-27.34×
EV / Sales	1.55×
Earnings Yield	-23.61%
Free Cash Flow Yield	-4.66%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$158.46M
Revenue (TTM)	$102.16M
Net Income (TTM)	-$35.85M
Free Cash Flow (TTM)	-$3.98M
Net Debt	$6.60M
Working Capital	$75.28M
Gross Margin	44.32%
Operating Margin	-22.27%
Net Margin	-34.94%
Return on Equity	-38.72%
Return on Invested Capital	-18.97%